Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the efficacy and safety of dasatinib 70 mg once daily
as first line therapy in patients with early chronic phase (CP) chronic myeloid leukemia
(CML).